April 15, 2025

Acurion Reveals New Branding and Fundraising Plans

Community Resource Consultants Inc. (CRCI)

Community Resource Consultants Inc. (CRCI) is a Michigan-based organization specializing in trauma rehabilitation medical case management. With over 34 years of experience, CRCI is dedicated to empowering survivors of catastrophic auto accidents to regain control of their lives and achieve both physical and emotional well-being. Their team of Licensed Master Social Workers (LMSWs) and Registered Nurses (RNs) are experts in navigating the complexities of today’s healthcare system, ensuring that survivors receive the necessary services for their recovery and rehabilitation. CRCI’s core values include advocacy, people, knowledge, and dependability, reflecting their commitment to being leading advocates and facilitators of long-term collaborative care.

News Summary

Acurion, formerly io9, has rebranded to enhance its mission in cancer care. With a new leadership team and groundbreaking technology, the company is launching a Series A fundraising on April 15, 2025, to revolutionize precision oncology and make innovative treatments more accessible for patients.

Acurion Unveils New Look and Plans for Series A Fundraising

In an exciting twist in the world of healthcare, Acurion, the company previously known as io9, has officially rebranded itself as part of a strategic shift aimed at better aligning with its mission to improve cancer care. With bold moves underway, Acurion is ready to take on the challenges of precision oncology in a big way. The rebranding reflects the company’s evolving vision for the future, and they are not slowing down anytime soon.

New Leadership Team Steers the Ship

As part of this fresh start, Acurion has appointed a new leadership team to guide the company into its next phase of growth. Leading this dynamic team is Rick Fultz, who brings over 15 years of experience in the life sciences sector. He is joined by Feng Cao, Ph.D., who will oversee operational management and regulatory strategies. The innovative minds don’t stop there; Ludmil Alexandrov, Ph.D., known for his significant contributions to cancer genomics, will serve as the Chief Scientific Officer, while Erik Bergstrom, Ph.D., a computational biology and AI expert, steps in as the Chief Technology Officer. Rounding out the team is Shelly Vandertie, who will focus on financial strategies as Vice President of Finance.

Making Precision Medicine Accessible

The heart of Acurion’s mission lies in enhancing the lives of cancer patients. The leadership team emphasizes the need to make precision medicine easily accessible. Currently, patients often face frustrating and costly delays in receiving timely treatment due to long waits for therapy selection after receiving a diagnosis. Acurion has set its sights on *dramatically shortening* this timeline.

OncoGaze™: A Game Changer

Enter Acurion’s groundbreaking technology, the OncoGaze™. Featured on CNN’s Global Innovations, this cutting-edge artificial intelligence platform is set to revolutionize cancer diagnostics. OncoGaze™ specializes in swiftly identifying genomic biomarkers from tumor biopsy slides. In fact, this platform slashes the time required to initiate first-line treatment from weeks to mere seconds, ensuring that patients receive the care they need as quickly as possible.

With an accuracy that surpasses even FDA-approved genomic testing, Acurion’s technology stands out as the only one of its kind published in the prestigious Journal of Clinical Oncology. The support from specialists in the oncology community continues to grow, reflecting a shared enthusiasm for how OncoGaze™ can transform cancer care.

Looking Ahead: Series A Fundraising Plans

As Acurion continues its upward trajectory, the company is gearing up to launch its Series A fundraising on April 15, 2025. This fundraising initiative will be pivotal in supporting ongoing growth and innovation in the field of precision oncology. Collaborating with research institutions, patient advocacy groups, and industry leaders, Acurion is poised to enhance its efforts in providing oncologists with vital genomic insights that will expedite treatment for cancer patients.

Dreams of Revolutionizing Frontline Cancer Care

The ultimate goal for Acurion is to completely transform frontline cancer care. By ensuring oncologists have access to accurate and timely genomic data, Acurion aims to significantly improve treatment delivery for those battling cancer. The company is working tirelessly to make precision therapies not just a concept but a reality for patients worldwide.

With its new branding, leadership team, and groundbreaking technology, Acurion is on a mission to make waves in precision oncology. The excitement is palpable, and the healthcare industry is watching closely as this innovative company embarks on its journey to change the course of cancer treatment for the better.